Recursion acquires Vium for drug discovery

By The Science Advisory Board staff writers

July 28, 2020 -- Recursion has acquired Vium to advance its technologies and grow its drug discovery pipeline of over 30 programs.

Vium's platform combines computer vision, machine learning, and sensor technologies to noninvasively collect and derive insights from digital biomarkers in preclinical in vivo research. The acquisition will augment Recursion's in vitro datasets and bolster its core technologies.

Financial terms of the acquisition were not disclosed.

Flywheel unveils life sciences imaging platform
Research informatics firm Flywheel has introduced an enterprise-wide image management platform geared for the life sciences market.
Big data analysis of images may aid vaccine development
A new pipeline that combines high-dimensional microscopy with big data analysis to gain molecular insights in T-cell biology and vaccine development was...
How AI is speeding development of COVID-19 therapies
As the world is facing a new challenge in trying to both adapt to and defend itself against the novel coronavirus, artificial intelligence (AI) is offering...

Copyright © 2020

Microscopy and Microanalysis Meeting
July 31 - August 4
Portland, Oregon United States
Glasgow International Health Festival
August 24-27
Glasgow, Glasgow City United Kingdom
Pharma Competitive Intelligence Conference and Exhibition
September 21-22
Newark, New Jersey United States
BioProcess International (BPI) Conference
September 27-30
Boston, Massachusetts United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter